Mitsi A. Blount, Ph.D.
Affiliations: | 2006 | Vanderbilt University, Nashville, TN |
Area:
BiochemistryGoogle:
"Mitsi Blount"Mean distance: 11.26 | S | N | B | C | P |
Parents
Sign in to add mentor| Jackie David Corbin | grad student | 2006 | Vanderbilt | |
| (Phosphodiesterase -5 (PDE5) exists in two inter-converted forms that are revealed by binding of ligands to the catalytic site.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Himmel NJ, Rogers RT, Redd SK, et al. (2021) Purinergic signaling is enhanced in the absence of UT-A1 and UT-A3. Physiological Reports. 9: e14636 |
| Himmel NJ, Wang Y, Rodriguez DA, et al. (2018) Chronic lithium treatment induces novel patterns of pendrin localization and expression. American Journal of Physiology. Renal Physiology |
| Sim JH, Himmel NJ, Redd SK, et al. (2014) Absence of PKC-alpha attenuates lithium-induced nephrogenic diabetes insipidus. Plos One. 9: e101753 |
| Francis SH, Blount MA, Corbin JD. (2011) Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiological Reviews. 91: 651-90 |
| Corbin JD, Foster TL, Bessay E, et al. (2011) Metal ion stimulators of PDE5 cause similar conformational changes in the enzyme as does cGMP or sildenafil. Cellular Signalling. 23: 778-84 |
| Bessay EP, Blount MA, Zoraghi R, et al. (2008) Phosphorylation increases affinity of the phosphodiesterase-5 catalytic site for tadalafil. The Journal of Pharmacology and Experimental Therapeutics. 325: 62-8 |
| Blount MA, Zoraghi R, Bessay EP, et al. (2007) Conversion of phosphodiesterase-5 (PDE5) catalytic site to higher affinity by PDE5 inhibitors. The Journal of Pharmacology and Experimental Therapeutics. 323: 730-7 |
| Bessay EP, Zoraghi R, Blount MA, et al. (2007) Phosphorylation of phosphodiesterase-5 is promoted by a conformational change induced by sildenafil, vardenafil, or tadalafil. Frontiers in Bioscience : a Journal and Virtual Library. 12: 1899-910 |
| Corbin J, Bessay EP, Blount MA, et al. (2007) Negative feedback control of the nitric oxide/cGMP pathway in smooth muscle Bmc Pharmacology. 7 |
| Blount MA, Zoraghi R, Ke H, et al. (2006) A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization. Molecular Pharmacology. 70: 1822-31 |